Abstract:OBJECTIVETo investigate the mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy (DCM) by valsartan.METHODSForty male wistar rats were randomly divided into 3 groups: DCM group, n = 16, fed with high-fat diet for 4 weeks and injected intraperitoneally with streptozocin (STZ) once to induce hyperglycemia so as to construct a DCM model, and then perfused into the stomach with normal saline; valsartan group, n = 16, to be constructed into DCM model and then perfused into the stomach with valsartan once daily; and control group (n = 8, fed with normal food and perfused into the stomach with normal saline. Four weeks after feeding (i.e., before injection of STZ), 1 week after STZ injection, and by the end of experiment after 12-hour fasting samples of venous blood were collected to detect the contents of triglyceride and fasting blood-glucose and insulin; by the end of experiment miniature cardiac catheter was inserted into the left ventricle to conduct hemodynamic examination. Then myocardium tissues were collected, collagen content was detected by Masson staining, real-time RT-PCR was used to detect the mRNA expression of thrombospondin (TSP)-1 and tumor growth factor (TGF)-beta(1) mRNA, expression, and Western blotting was used to detect the protein expression of TSP-1, active TGF-beta(1) (A-TGF-beta(1)) and latent TGF-beta(1) (L-TGF-beta(1)).RESULTSBy the end of the experiment, the body weights, and insulin sensitivity index were significantly lower and fasting blood-glucose, and serum triglyceride and cholesterol were significantly higher in the DCM group and valsartan group in comparison with those in the control group (all P < 0.01), however, there was no significant differences in fasting insulin among these 3 groups. The values of left ventricular systolic pressure (LVSP) and +/- dp/dt(max) were significantly lower and left ventricular end diastolic pressure were significantly higher in the DCM group in comparison with the control group (all P < 0.01). The LVSP and -dp/dt(max) were significantly higher and LVEDP was significantly lower in the valsartan group than in the DCM group (all P < 0.05). The LVEDP was significantly higher and -dp/dt(max) was significantly lower in the valsartan group than in the control group. Electron microscopy showed the distribution of a great amount of collagen in the myocardial interstitial tissue. The collagen content of the DCM group was 17 +/- 3, significantly higher than that of the control group (11 +/- 3, P < 0.05), and the collagen content of the valsartan group was 13 +/- 3, significantly lower than that of the DCM group (P < 0.05). The mRNA expression of TSP-1 and that of TGF-beta(1) were significant higher in the DCM group than in the control group (both P < 0.05), and were significantly lower in the valsartan group than in the DCM group (both P < 0.05); however, the TGF-beta(1) mRNA expression in the valsartan group was significantly higher in the valsartan group than in the control group (P < 0.05). The values of protein expression of TSP-1, A-TGF-beta(1) and L-TGF-beta(1) were all significantly higher in the DCM group than in the control group (all P < 0.05), and the values of protein expression of TSP-1 and A-TGF-beta(1) in the valsartan group were both significantly lower than those in the DCM group (both P < 0.05), however, there was no significant difference in the protein expression of L-TGF-beta(1) between the valsartan group and DCM group.CONCLUSIONValsartan amelioorates myocardial interstitial fibrosis in DCM via TSP-1/TGF-beta(1) signaling pathway.

Effect of SKF96365 on Myocardial Fibrosis in Type-II Diabetic Rats

[Effects of Insulin-Like Growth Factor-1 on the Myocardium in Diabetic Rats].

Fluvastatin Attenuates Myocardial Interstitial Fibrosis and Cardiac Dysfunction in Diabetic Rats by Inhibiting Over-Expression of Connective Tissue Growth Factor

The effect of different ACEIs on myocardial interstitial fibrosis in diabetic rat

Effects of Fluvastatin on Myocardial Interstitial Fibrosis and Cardiac Function in Diabetic Rats

Relationship Between Expression of Α Smooth Muscle Actin and Diabetic Nephropathy in Rats

[Mechanism of Reversion of Myocardial Interstitial Fibrosis in Diabetic Cardiomyopathy by Valsartan].

The Protective Effect of Simvastatin on Myocardial Fibrosis of Rats with Diastolic Heart Failure

Rosuvastatin Inhibits TGF-beta1 Expression and Alleviates Myocardial Fibrosis in Diabetic Rats.

Therapeutic Effect of Trichosanthes Fruit Extract on Myocardial Fibrosis in Streptozotocin Induced Diabetic Mice

THE EFFECT OF PHYCOCYANIN ON THE EXPRESSION OF Inos IN MYOCARDIAL CELLS OF TYPE 2 DIABETES MELLITUS IN RATS

ASSA13-03-38 Selenium Ameliorate Myocardial Fibrosis in Diabetic Rats Through Inhibiting GPx- ROS-Smad- CTGF Signalling Pathway

Effects of erythropoietin on myocardial interstitial fibrosis and cardiac function in diabetic rats

Fibrosis And Cardiac Dysfunction In Insulin-Resistant Rats: Changes In Myocardial Type I Collagen And Telmisartan'S Effects

Protective effect of SIRT 1 agonist on myocardium in diabetic mice

Inhibition of farnesyl pyrophosphate synthase alleviates cardiomyopathy in diabetic rat

Effect of Insulin Combined with Selenium on Myocardial Remodeling in Diabetic Rats

Activation of Kir2.1 Improves Myocardial Fibrosis by Inhibiting Ca2+ Overload and the TGF-β1/Smad Signaling Pathway

Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2 diabetes myocardial-fibrosis model

Effect of exercise on gene expression of calcium modulin in myocardial sarcoplasmic reticulum of diabetic rat